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Original research article
Rapid testing and treatment for sexually
transmitted infections improve patient
care and yield public health benefits
Gary G Whitlock1, Daniel C Gibbons2,3, Nick Longford4,
Michael J Harvey2, Alan McOwan1 and Elisabeth J Adams2,5
Abstract
A service evaluation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing and result notification in
patients attending a rapid testing service (Dean Street Express [DSE]) compared with those attending an existing
‘standard’ sexual health clinic (56 Dean Street [56DS]), and modelling the impact of the new service from 1 June
2014 to 31 May 2015. Primary outcome: time from patients’ sample collection to notification of test results at DSE
compared with 56DS. Secondary outcomes estimated using a model: number of transmissions prevented and the
number of new partner visits avoided and associated cost savings achieved due to rapid testing at DSE. In 2014/15,
there were a total of 81,352 visits for CT/NG testing across 56DS (21,086) and DSE (60,266). Rapid testing resulted in a
reduced mean time to notification of 8.68 days: 8.95 days for 56DS (95% CI 8.91–8.99) compared to 0.27 days for DSE
(95% CI 0.26–0.28). Our model estimates that rapid testing at DSE would lead to 196 CT and/or NG transmissions
prevented (2.5–97.5% centile range¼ 6–956) and lead to annual savings attributable to reduced numbers of partner
attendances of £124,283 (2.5–97.5% centile range¼ £4260–590,331). DSE, a rapid testing service for asymptomatic
infections, delivers faster time to result notification for CTand/or NG which enables faster treatment, reduces infectious
periods and leads to fewer transmissions, partner attendances and clinic costs.
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Introduction
The number of sexually transmitted infections (STIs)
diagnosed in England continues to rise annually, par-
ticularly in groups such as young people and men who
have sex with men (MSM).
Chlamydia trachomatis (CT) is often asymptomatic
but is also associated with pelvic inflammatory disease,
epididymo-orchitis and infertility. It is the most com-
monly diagnosed STI in genitourinary medicine
(GUM) clinics in England, with over 200,000 diagnoses
representing nearly 50% of all STI diagnoses in 2015.1,2
Neisseria gonorrhoeae (NG) diagnoses increased by
53% between 2012 and 2015 (26,880–41,193 cases).
These increases may have resulted from changes in
sexual behaviour, improved access to services,
increased screening and advances in the accuracy and
reliability of diagnostic technology.3
The UK Department of Health’s Framework for
Sexual Health Improvement in England called for
interventions and actions to improve sexual health out-
comes.4 In particular, it mentioned that incorporating
the latest technologies into clinical settings provided an
opportunity to create sexual health services that
improve access, provide prompt diagnosis and treat-
ment, and reduce costs.
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Theoretical work has shown that a rapid testing and
treatment service for STIs could reduce complications,
transmissions, inappropriate treatment and generate £10
million in cost savings to providers if implemented across
England.5 In February 2014, Chelsea & Westminster
NHS Foundation Trust opened Dean Street Express
(DSE), a part of 56 Dean Street (56DS), in Soho,
London, offering a walk-in, rapid STI screening service
for asymptomatic individuals.6 This is the first rapid test-
ing service of its kind in the UK.
Information on the volume and results of testing,
patient service utilisation patterns and time from test
to results notification is available from DSE and 56DS
for all patients in Chelsea & Westminster NHS Trust.
This provides an opportunity to test the theory that
rapid testing and results supports improved sexual
health services and yields a public health benefit. In
this service evaluation, we assess the impact that DSE
has had on patient care and estimate the public health
benefit attained as a result of faster treatment for asymp-
tomatic patients compared to conventional sexual health
clinics. We also explore the potential impact on reducing
transmissions to new partners by shortening the period
between testing and treatment, and the subsequent
reduction in partner treatment visits and associated cost.
Methods
As a service evaluation, ethics approval was not
sought. We used SQUIRE guidelines in writing this
evaluation.
56DS
Prior to the opening of DSE, both asymptomatic and
symptomatic patients were seen at 56DS and processing
ofCTandNGsampleswas carriedoutoff-site.AfterDSE
opened, symptomatic patients continued to be seen at
56DSwith the same testingmodel; asymptomatic patients
were tested at DSE with on-site rapid NAAT testing.
56DS is a publicly-funded, confidential STI service
for symptomatic patients and offers broader services
such as emergency contraception and post-exposure
HIV prophylaxis for sexual exposure.
During the observation period, 56DS used standard
off-site laboratory-based nucleic acid amplification test
(NAAT) testing for CT and/or NG. Test results at
56DS were manually reviewed and actioned. Patients
with negative tests were sent an SMS to inform them of
their result; patients with positive tests were contacted
by SMS if they had received empirical treatment at
their initial visit to perform partner notification.
Patients with positive test results who had not been
given treatment at their initial visit were called by
clinic staff to arrange a follow-up appointment.
DSE
DSE is a free, confidential, walk-in STI clinic for men
and women without symptoms of STIs, which opened in
February 2014. On arrival at DSE, patients complete a
short questionnaire on their sexual history using a
touchscreen computer. The touchscreen orders the rele-
vant swabs based on their self-reported sexual history.
Patients are directed to a cubicle where they take their
own swabs/samples according to the directions in a short
video. Samples are then immediately delivered to the in-
house laboratory via air tube and are processed by a
NAAT on the GeneXpert Infinity machine (Cepheid,
Sunnyvale, CA, USA). Finally, patients have a consulta-
tion with a health adviser to review their sexual history
andhaveblood taken for syphilis,HIVand/orhepatitisB/
C testing at an off-site laboratory with results notified
within four hours. Empirical treatment for STIs and con-
tactsofSTIs isnot givenatDSE.Attenderswhoare symp-
tomatic and those who reveal they are the contact of
infections are directed to 56DS for management and/or
treatment. However, patients receiving empirical treat-
ment (because of being symptomatic and/or a partner)
were not considered in this analysis.
Results from the GeneXpert machine and blood test
results are integrated into the clinic’s electronic patient
records (EPR), which allows for automatic collation
and delivery of results to patients by SMS. Patients
with positive test results are offered treatment at
56DS as soon as possible. More information about
the service and a film of the patient pathway within
clinic can be accessed online (http://www.deanstreetex
press.nhs.uk/).
Data analysis
EPR data from 56DS and DSE were extracted for the
one-year period from 1 June 2014 to 31 May 2015
inclusive. This period was selected to allow a ‘bedding
in’ period following the launch of DSE. The following
data were available for each patient-testing attendance:
anonymous patient ID, clinic site, date of clinic atten-
dance, gender and sexual orientation (MSM, men who
have sex with women [MSW] and women). The date
and time of CT/NG result notification by patient ID
were extracted.
From patient notes, we extracted data on the
number of reported new partners in the last three
months for a sample of patients attending DSE over
a one-week period (27 April 2015–2 May 2015), as this
was incomplete for all patient records in the EPR. In
order to be representative of patients attending over the
week, we selected the first 12 patients for the 15 sessions
over the week (morning, afternoon, evening sessions),
from MSW, MSM and women.
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The total number of CT/NG testing episodes at DSE
and 56DS was estimated as the total of all attendances in
which English national coding data (GUMCAD1) indi-
cated that CT/NG tests occurred: T2 (CT and NG), T3
(CT, NG and syphilis) or T4 (CT, NG, syphilis and
HIV) were reported. Testing code T1 (CT only) was
excluded as CT testing in isolation is not standard prac-
tice. The date and time on which patients had a testing
appointment, and the date and time that their test results
for CT/NG were sent via SMS were matched using
patient IDs.
The time from clinic visit to sending CT/NG results
was calculated for each patient, to quantify the delay to
notification by clinic site.
Model description and analysis
A model was developed to estimate the potential
impact of introducing a rapid testing service for asymp-
tomatic patients at DSE. Rapid testing for asymptom-
atic patients was not performed at 56DS at any point
during this evaluation. Therefore, the model estimated
the impact of the reduction in time to result notification
as if asymptomatic patients had attended 56DS rather
than DSE and their CT/NG tests had been processed in
that service. The model estimates the reduction in
number of new sexual partners who are spared exposure
to CT and/or NG for those with asymptomatic infection
with rapid testing compared with slower standard off-
site testing. By modelling the reduction in new sexual
partners’ exposure, we estimate the reduction in partner
notification and treatment (for partners exposed to CT/
NG), the cost to clinics for fewer attendances for screen-
ing and treatment of partners, and potential public
health impact due to transmissions averted.
Results
Clinical data
In 2014/15, there were a total of 81,352 visits for CT/
NG testing across 56DS (21,086) and DSE (60,266).
The volume of testing attendances increased from an
initial five-day moving average of 152.7 per day to
Figure 1. Moving average of daily attendances for testing at Dean Street Express (DSE) and 56 Dean Street (56DS) over the
observation period. Plots represent a moving daily average (period¼ 5 days) of tests performed at DSE or 56DS. Dashed lines
represent the output of unadjusted linear regression of the moving five-day average of daily testing attendances versus attendance date
and are provided for illustrative purposes only (p for trend¼<0.001 and 0.088 for DSE and 56DS, respectively).
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241.0 per day at DSE over the observation period (p for
trend¼< 0.001), a relative increase of 58% over the
year. The volume of testing attendances at 56DS
remained relatively static (p for trend¼ 0.088) over
the observation period (Figure 1). The time between
patients’ sample collection and notification of CT and
NG test results at DSE and 56DS over the observation
period are shown in Figure 2.
Visits for CT/NG testing generated a total of 40,982
CT/NG test notifications from 56DS and 102,060 from
DSE. Ninety-seven per cent of these results (138,936)
were matched to data describing dates and times for
testing and result notification. Of these, 138,261
(99.5%) were eligible for inclusion (delay between
time of appointment and test notification is positive
and  30 days).
The mean delay between eligible pairs of clinic
appointments and test result notifications was
8.95 days (95% CI 8.91–8.99 days) for 56DS and
0.27 days (95% CI 0.26–0.28 days) at DSE (Figure 2).
This resulted in a reduction in time to result notification
of 8.68 days.
Data on the mean (and median) number of new
partners in the past three months for women, MSW
and MSM were 1.82 (1), 1.93 (1) and 3.78 (2), respec-
tively (distribution show in Figure 3).
The distributions used for our Monte Carlo simula-
tions were based on our observed results and data
from existing literature; the distributions and their
coefficients are described in the supplementary table
(Table 2 in Appendix 1).
Our model estimated that implementing a rapid
CT/NG testing service at DSE led to 854 partner
attendances averted (2.5–97.5% centile range¼ 31–
4040), prevented 196 CT and/or NG transmissions
(2.5–97.5% centile range¼ 6–956) and led to annual
savings attributable to reduced numbers of partner
attendances of £124,283 (IQR¼ £4260–590,331).
Discussion
The rapid STI testing service at DSE has reduced
the time from clinic attendance for asymptomatic
CT and NG testing and notification of results by
over a week to a few hours – a relative reduction
of 97%. Adoption of rapid CT/NG testing has the
potential to realise a number of ‘knock-on’ public
health benefits, some of which are incorporated
into our model: fewer transmissions and partners to
contact trace, and fewer tests and empirical treatments
for contacts. Our findings complement analyses dem-
onstrating the savings in baseline costs associated
with deployment of rapid testing in open-access
GUM clinics.5,7
The ability of DSE to consistently deliver rapid test-
ing and notification of CT/NG samples is, in part, due
to the lean service delivery model that has been
adopted. The service was designed to minimise the
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number of steps involved in the patient journey and
the management of test results. The direct linkage
between the results data generated by the GeneXpert
platform and DSE’s EPR system enables the clinic to
notify patients as they become available, compared to
relying on manual result collection and notification.
Although not captured in our analysis, it will also
mean less staff time (and costs) to notify patients
of results.
Concerns about the potentially deleterious effect
that the immediacy of result notification may have on
patient willingness to attend for testing have been
raised by other studies examining the role of rapid
tests for CT and NG.8,9 Conversely, daily demand for
the rapid testing service offered at DSE has increased
by 59% over the observation period. This may indicate
that the DSE services have answered an unmet need for
rapid STI testing and treatment services.
Our study is based on a large sample of patients
across two clinic sites over the same year-long obser-
vation period, minimising any transient seasonal differ-
ences in sexual behaviours, patterns of social mixing,
prevalence or health-seeking behaviours. Whilst our
simulations show a wide range in the distribution of
savings, rapid test notification consistently leads to
monetary benefits across the various combinations of
input parameters in our simulations.
There are several limitations to this analysis. First,
our results may not be wholly generalizable to other
settings across the UK and internationally due to dif-
ferences in which patients access services or how these
services are delivered. The majority of NG/CT tests in
DSE and 56DS are in MSM, whereas nationally MSM
account for 12% of STI testing episodes tests.1
This suggests that there may not be as large a public
health benefit, as MSM have higher rates of new part-
ners than MSW and women. However, clinics outside
central London could still benefit from the same model
of rapid testing and faster treatment, in terms of reduc-
tions in transmissions and partner treatment visits
averted.
Second, we did not have access to the paired
GeneXpert-EPR data from the clinic for notification
of results. This meant that we could not directly cate-
gorise CT and/or NG positivity rates by gender
and sexual orientation. Instead, we relied on proxy
measures to identify samples originating from MSM
and classify results as being from ‘MSM’ and ‘non-
MSM’. The anatomical site for each sample result
was unavailable. Third, whilst we know the exact
date and time attendees were notified of their results
via SMS, we do not know when they have read or
actioned the message. Fourth, we have not analysed
the impact of infections for bisexual or transgender
patients attending our service.
In this analysis, we assumed that the delay between
result notification and attendance for treatment is the
same; earlier analysis has shown this is similar for DSE
and 56DS.10,11 In the absence of other data, we have
used a low daily transmission probability for CT and
NG in our model, which may underestimate the mag-
nitude of public health benefits as a result of this service
reconfiguration. We have assumed that sexual behav-
iour with regards to new sexual partners remains the
same in the period between testing and receiving results
as before testing; if this is lower, it may overestimate
the impact of rapid testing. Because we took partner
data from a small sample of patients, we have missed
some of the patients who report very high numbers
of partners; this will reduce the mean and underesti-
mate the impact of DSE leading to more conservative
results. Also, those with CT and/or NG may have
higher partner numbers than those without infection
and our model has not modelled the impact of this,
perhaps underestimating the effects of rapid results.
Our model ignored any public health benefits of rap-
idly notifying for other infections tested at DSE such as
syphilis, HIV and hepatitis B and C.
Further research is warranted to assess the repro-
ducibility of the services offered at DSE in other clinics
in a range of rural and urban settings. It would also be
useful to estimate the initial set-up costs for the infra-
structure required for rapid testing and notification, the
effect this service may have on the systematic collection
of data describing the prevalence and patterns of anti-
microbial resistance and what impact expanding rapid
testing to other organisms such as syphilis and HIV
may have.
Although we have not modelled the effect that rapid
testing may have on the prevalence of CT and NG
beyond the potential for shortening infectious periods
and subsequently decreasing the number of transmis-
sion opportunities, existing evidence indicates that
rapid CT/NG testing has the potential to considerably
reduce the prevalence of CT and NG.
Our evaluation provides real-world evidence to
enable decision-makers and commissioners to rational-
ise expenditure and maximise outcomes when consid-
ering the funding and structure of their STI services.
It shows the unmet need for a rapid testing service
based on the large increases in patient attendances,
and the potential public health benefits and cost
savings of implementing such a service.
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Appendix 1
The model calculated results separately for MSM,
MSW and women, and then results were added togeth-
er. Input parameters came from observed data (Table
1) and published sources (Table 2).12–17 We also deter-
mined the positivity rates for CT and NG in patients
attending DSE by taking CT/NG test results from
DSE’s GeneXpert platform, as this was unavailable
directly from the EPR. The test reference numbers
incorporated an embedded unique patient identifier
and therefore multiple samples could be correctly
attributed to a single patient.
Direct linkage of GeneXpert data to clinic EPRs was
precluded by the absence of a global patient identifier,
making disaggregation of test results by gender and
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sexual orientation impossible. Data were unavailable to
determine the anatomical site of each sample.
Therefore, we assumed that any patients who had
three samples (urine, rectal and throat swabs) taken
on the same date were MSM.
A patient was considered positive for CT and/or NG
on a specific date if any of the samples from their batch
of tests was reported as positive. Co-positivity on a
given date was defined as a patient testing positive
for both infections across any of their results from a
given batch (i.e. sample 1 tested positive for both CT
and NG or sample 1 tested positive for CT and sample
2 tested positive for NG). Estimated patient positivity
was used to estimate point prevalence of CT, NG and
co-infection with CT and NG.
The primary outputs from this model were the
number of transmissions avoided, the partner attend-
ances averted as a direct result of reductions in time to
notification and treatment and the cost savings from
reduced attendances. We assumed that there would
be no difference in the time from notification of a pos-
itive result to attending for treatment by clinic site;
hence, the potential benefits are approximated by the
reduced time from sample collection to notification of
results with a rapid test. We also assumed that the rate
of sexual partner change remains the same after testing
at DSE.
The total number of infections was estimated
by multiplying the annual number of attendances
for CT/NG testing using DSE data by the proportion
of samples with positive results for CT, NG or
both. This was thought to better approximate the
number of infections than the diagnostic codes from
the clinic, as this was inconsistently assigned to either
the testing visit retrospectively or the follow-up treat-
ment visit.
In the absence of robust observed data, the daily
transmission probabilities for CT and NG were
Table 1. Descriptive statistics of patient attendances, number of sexual partners, CT and/or NG positivity and days between
attendance and notification of test results for 56 Dean Street and Dean Street Express.
56 Dean Street Dean Street Express Overall
n % n % n %
Attendancesa MSW 4856 19% 13,100 13% 17,956 17%
MSM 24,726 58% 39,373 65% 64,099 60%
Women 8336 23% 15,856 22% 24,192 23%
Total 37,918 100% 68,329 100% 106,247 100%
Attendances for
CT/NG testing
MSW 3020 14% 12,053 20% 15,073 19%
MSM 13,293 63% 33,348 55% 46,641 57%
Women 4773 23% 14,865 25% 19,638 24%
Total 21,086 100% 60,266 100% 81,352 100%
n with data Mean
New sexual partners in
past three months
MSW 224 1.93
Women 224 1.82
MSM 224 3.78
Mean SD
CT positivity MSW/females 3.65% 0.42%
MSM 6.39% 0.52%
NG positivity MSW/females 1.70% 0.27%
MSM 11.21% 0.88%
Co-positivity MSW/females 0.02% 0.06%
MSM 1.27% 0.27%
Mean SD Mean SD Mean SD
Days between attendance
and result notification
8.95 4.43 0.27 0.82
CT: Chlamydia trachomatis; MSM: men who have sex with men; MSW: men who have sex with women; NG: Neisseria gonorrhoeae.
aThree attendances were excluded from analysis on the basis of missing gender data.
Model coding, input parameterisation, input sampling and tabulation of results were performed in R V3.3.0 for Windows; data visualisations were
constructed in Tableau V10.0 for Windows. Statistical significance was assumed at a¼ 0.05.
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assumed to be 5% (SD 1%) and 10% (SD 2%), respec-
tively, based on the estimations of Turner et al.5 and
accounts for variations in condom use, type of sex acts
and number of sex acts per partner per day. The
transmission probability of a dual-positive individual
passing on either CT, NG or both was estimated
under the assumption that the probabilities of
transmitting either infection were independent (i.e.
PðCT [NGÞ ¼ PðCTÞ þ PðNGÞ.
The cost of a GUM attendance for partners was
assumed to be the mean of the single and multi-
professional first attendance (£135) from the draft
non-mandatory UK National Tariff for 2016/17.10
Patients that test positive are advised at the treat-
ment visit that their partners also need to attend for
treatment. According to Estcourt et al.,18 approximate-
ly 41.9% (95% CI 39.1–44.6%) of a positive patient’s
partners will attend a GUM clinic for treatment. We
assumed that asymptomatic patients who had a test
will not alter their sexual behaviour whilst awaiting
test results. Therefore, we estimated the mean number
of partner clinic appointments that could be averted by
using a rapid test by multiplying the daily number of
partners and the reduction in turnaround time by the
estimated partner attendance. The number of averted
clinic visits was multiplied by the tariff reimbursement
per visit.
A Monte Carlo simulation was performed to assess
the robustness of the estimated outcomes. We ran the
model over 100,000 combinations of input parameters,
each independently sampled from appropriate distribu-
tions that were fitted according to the characteristics of
the data or selected as the optimal fit (based on the
Akaike Information Criterion) to the observed data
(Table 1), or by using the raw data (Table 2).
Table 2. Characteristics of parameter distributions used in Monte Carlo simulations.
Variable
Sampling
distribution
Distribution
characteristics Source/note
CT positivity MSM Log-normalb x ¼2.75, r¼ 0.02
MSW/womena Log-normalb x ¼3.31, r¼ 0.03
NG positivity MSM Log-normalb x ¼2.18, r¼ 0.02 DSE GeneXpert
platformMSW/Womena Log-normalb x ¼4.06, r¼ 0.04
Co-positivity MSM Log-normalb x ¼4.36, r¼ 0.05
MSW/Womena Log-normalb x ¼6.62, r¼ 0.14
New partners in past
three months
Sampled directly
from raw data,
with replacement
Proportion of partners attending Log-normalb x ¼0.87, r¼ 0.07 Estcourt et al.18
Time (days) to notification DSE Log-normal x ¼1.70, r¼ 0.63 Clinic EPRs
56DS Weibull Shape¼ 2.01, Scale¼ 10.00
Daily transmission
probability (per partner)
CT Log-normalb x ¼3.00, r¼ 0.20 Turner et al.5
NG Log-normalb x ¼2.30, r¼ 0.20
CT: Chlamydia trachomatis; DSE: Dean Street Express; EPR: electronic patient record; MSM: men who have sex with men; MSW: men who have sex with
women; NG: Neisseria gonorrhoeae.
aThe positivity in MSW/women was estimated from samples in which only one sample was done within 24 h per patient ID. No data on patient
characteristics were available to differentiate MSW and women.
bIndicates distribution fitted and parameterised a priori according to the characteristics of the underlying data for this variable. Parameters for
lognormal distributions were derived from observed means and standard deviations of source data.
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